期刊文献+

无关供者造血干细胞移植治疗重型再生障碍性贫血29例的疗效分析 被引量:4

Outcome of unrelated-donor allogeneic hematopoietic cell transplantation for 29 recipients with severe aplastic anemia
原文传递
导出
摘要 目的 评估无关供者异基因造血干细胞移植(URD allo-HSCT)治疗重型再生障碍性贫血(SAA)的效果,及其与HLA全相合同胞供者allo-HSCT(MSD allo-HSCT)的差异.方法 根据供者来源不同,将2001年10月至2016年12月64例接受alb-HSCT治疗的SAA患者分为无关供者组(URD组,29例)和全相合同胞供者组(MSD组,35例).比较两组受者的移植效果及相关并发症发生情况.结果 URD组与MSD组移植后造血功能重建情况,排斥反应发生率的差异均无统计学意义(P均>0.05).URD组Ⅱ~Ⅳ度急性移植物抗宿主病(GVHD)和慢性GVHD的发生率明显高于MSD组(30.76%与8.57%,P=0.026;26.92%和5.71%,P=0.021).两组受者移植后肺部感染、巨细胞病毒血症、EB病毒血症和出血性膀胱炎的发生率相似.MSD组与URD组受者预计5年总体存活率(OS)分别为(73.6±8.7)%和(72.7±9.5)%(P=0.878),预计5年无SAA复发存活率(DFS)分别为(73.6±8.7%)%和(70.3±10.2) %(P=0.668).结论 URD allo-HSCT治疗SAA的疗效与MSD allo-HSCT相当,在无HLA全相合同胞供者时可作为SAA患者的一线治疗选择. Objective To assess the effectiveness of unrelated donor (URD) allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of severe aplastic anemia (SAA),and the difference between URD allo-HSCT and matched sibling donor (MSD) allo-HSCT.Methods According to the source of donors,the SAA patients subject to allo-HSCT were divided into MSD allo-HSCT group (MSD group) and URD allo-HSCT group (URD group) from October 2001 to December 2016 in Henan Cancer Hospital.The efficacy and transplantation related complications were compared between two groups.Results There were no statistically significant differences in hematopoietic reconstitution and graft rejection between two groups.The incidence of grade Ⅱ-Ⅳ acute GVHD and chronic GVHD was higher in the URD group than in the MSD group (30.76% vs.8.57%,P =0.026;26.92% vs.5.71%,P =0.021).However,other transplant-related complications including pulmonary complications and hemorrhagic cystitis,incidence of EBV and CMV reactivation and venous occlusive disease showed no significant difference between two groups.The estimated 5-year over survival was (73.6 ± 8.7) % in the MSD group and (72.7 ± 9.5) % in the URD group (P =0.878).There was no significant difference in 5-year disease-free survival between two groups (73.6 ± 8.7% vs.70.3 ± 10.2,P =0.668).Conclusion URD-HSCT is a novel treatment approach and could be considered as first-line therapy in selected patients without MSD.
出处 《中华器官移植杂志》 CAS CSCD 2017年第2期78-83,共6页 Chinese Journal of Organ Transplantation
关键词 再生障碍性贫血 造血干细胞移植 无关供者 同胞供者 Severe aplastic anemia Hematopoietic stem cell transplantation Unrelated donor Matched sibling donor
  • 相关文献

参考文献1

二级参考文献4

  • 1Passweg JR,Pérez WS,Eapen M. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia[J].Bone Marrow Transplantation,2006,(07):641-649.doi:10.1038/sj.bmt.1705299. 被引量:1
  • 2Deeg HJ,O'Donnell M,Tolar J. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy[J].Blood,2006,(05):1485-1491. 被引量:1
  • 3Ommati LV,Rodrigues CA,Silva AR. A retrospective comparison of cyclophosphamide plus antithymocyte globulin with cyclophosphamide plus busulfan as the conditioning regimen for severe aplastic anemia[J].Brazilian Journal of Medical and Biological Research,2009,(03):244-250. 被引量:1
  • 4Saito AM,Chiba S,Ogawa S. Long-term sustained mixed chimerism after allogeneic stem cell transplantation in a patient with severe aplastic anemia[J].Internal Medicine,2007,(23):1923-1926.doi:10.2169/internalmedicine.46.0249. 被引量:1

共引文献5

同被引文献43

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部